World’s first gene therapy to be withdrawn in from market in Europe – Science Business
Science Business |
World's first gene therapy to be withdrawn in from market in Europe
Science Business Four and a half years after making history and getting European Medicines Agency approval for the first gene therapy in a regulated market, uniqure NV is throwing in the towel and will not apply for the license to be renewed when its expires on 25 October. Gene Therapy 2017 News: First Gene Therapy Drug Worth $1M, Withdrawn Due to Lack of Demand EMA designates uniQure's gene therapy for hemophilia a priority UniQure's haemophilia B therapy picks up PRIME status |
